Acticor Biotech SAS
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Pha… Read more
Acticor Biotech SAS (ALACT) - Net Assets
Latest net assets as of June 2024: €-5.29 Million EUR
Based on the latest financial reports, Acticor Biotech SAS (ALACT) has net assets worth €-5.29 Million EUR as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€10.22 Million) and total liabilities (€15.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-5.29 Million |
| % of Total Assets | -51.74% |
| Annual Growth Rate | N/A |
| 5-Year Change | -158.82% |
| 10-Year Change | -128.77% |
| Growth Volatility | 225.59 |
Acticor Biotech SAS - Net Assets Trend (2007–2023)
This chart illustrates how Acticor Biotech SAS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Acticor Biotech SAS (2007–2023)
The table below shows the annual net assets of Acticor Biotech SAS from 2007 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €-5.31 Million | -136.87% |
| 2022-12-31 | €-2.24 Million | -120.36% |
| 2021-12-31 | €11.02 Million | +542.07% |
| 2020-12-31 | €1.72 Million | -81.00% |
| 2019-12-31 | €9.03 Million | +44.83% |
| 2018-12-31 | €6.24 Million | +254.34% |
| 2017-12-31 | €-4.04 Million | -124.28% |
| 2016-12-31 | €16.64 Million | -2.75% |
| 2015-12-31 | €17.11 Million | -7.34% |
| 2014-12-31 | €18.47 Million | -4.97% |
| 2013-12-31 | €19.44 Million | +9.88% |
| 2012-12-31 | €17.69 Million | +14.20% |
| 2011-12-31 | €15.49 Million | +651.30% |
| 2010-12-31 | €2.06 Million | +47.89% |
| 2009-12-31 | €1.39 Million | +0.07% |
| 2008-12-31 | €1.39 Million | +240.59% |
| 2007-12-31 | €409.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Acticor Biotech SAS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36514.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €659.00K | % |
| Other Comprehensive Income | €-31.00K | % |
| Other Components | €37.39 Million | % |
| Total Equity | €-5.31 Million | 100.00% |
Acticor Biotech SAS Competitors by Market Cap
The table below lists competitors of Acticor Biotech SAS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aruma Resources Ltd
AU:AAJ
|
$2.13 Million |
|
TVD Holdings PCL
BK:TVDH
|
$2.13 Million |
|
Star Vault AB (publ)
PINK:SRVTF
|
$2.14 Million |
|
2F5
F:2F5
|
$2.14 Million |
|
Visionary Gold Corp
PINK:VIZNF
|
$2.13 Million |
|
Deltamac Taiwan Co Ltd
TWO:6144
|
$2.13 Million |
|
Dolphin International Bhd
KLSE:5265
|
$2.13 Million |
|
Emerson Radio Corporation
NYSE MKT:MSN
|
$2.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Acticor Biotech SAS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -2,243,000 to -5,313,000, a change of -3,070,000.
- Net loss of 18,640,000 reduced equity.
- New share issuances of 10,109,000 increased equity.
- Other comprehensive income decreased equity by 21,000.
- Other factors increased equity by 5,482,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-18.64 Million | -350.84% |
| Share Issuances | €10.11 Million | +190.27% |
| Other Comprehensive Income | €-21.00K | -0.4% |
| Other Changes | €5.48 Million | +103.18% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Acticor Biotech SAS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | €0.35 | €0.25 | x |
| 2011-12-31 | €4.55 | €0.25 | x |
| 2012-12-31 | €5.32 | €0.25 | x |
| 2013-12-31 | €5.87 | €0.25 | x |
| 2014-12-31 | €5.57 | €0.25 | x |
| 2015-12-31 | €5.16 | €0.25 | x |
| 2016-12-31 | €5.02 | €0.25 | x |
| 2017-12-31 | €-1.22 | €0.25 | x |
| 2018-12-31 | €2.03 | €0.25 | x |
| 2019-12-31 | €1.72 | €0.25 | x |
| 2020-12-31 | €0.27 | €0.25 | x |
| 2021-12-31 | €1.42 | €0.25 | x |
| 2022-12-31 | €-0.21 | €0.25 | x |
| 2023-12-31 | €-0.44 | €0.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Acticor Biotech SAS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-48.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 21.23% | 6.53% | 0.95x | 3.44x | €231.47K |
| 2011 | 10.78% | 15.79% | 0.49x | 1.39x | €120.04K |
| 2012 | 12.57% | 14.81% | 0.53x | 1.61x | €454.71K |
| 2013 | 10.07% | 11.17% | 0.53x | 1.69x | €14.51K |
| 2014 | -5.23% | -4.89% | 0.63x | 1.70x | €-2.81 Million |
| 2015 | -7.92% | -7.96% | 0.57x | 1.76x | €-3.07 Million |
| 2016 | -2.84% | -3.42% | 0.48x | 1.72x | €-2.14 Million |
| 2017 | 0.00% | -117.42% | 4.25x | 0.00x | €-9.96 Million |
| 2018 | -96.02% | -11978.00% | 0.00x | 1.83x | €-6.61 Million |
| 2019 | -55.94% | -326.47% | 0.10x | 1.71x | €-5.96 Million |
| 2020 | -450.47% | -480.29% | 0.15x | 6.42x | €-7.90 Million |
| 2021 | -119.87% | 0.00% | 0.00x | 1.62x | €-14.31 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-16.41 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-18.11 Million |
Industry Comparison
This section compares Acticor Biotech SAS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $13,112,693
- Average return on equity (ROE) among peers: -56.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Acticor Biotech SAS (ALACT) | €-5.29 Million | 21.23% | N/A | $2.13 Million |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $72.33 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $3.97 Billion |
| Adocia (ADOC) | $-6.91 Million | 0.00% | 0.00x | $84.57 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $5.01 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.84 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $29.13 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $23.45K |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $424.10K |